These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23591255)

  • 1. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial.
    Davison SL; Bell RJ; Robinson PJ; Jane F; Leech J; Maruff P; Egan GF; Davis SR
    Menopause; 2013 Oct; 20(10):1020-6. PubMed ID: 23591255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women.
    Joffe H; Hall JE; Gruber S; Sarmiento IA; Cohen LS; Yurgelun-Todd D; Martin KA
    Menopause; 2006; 13(3):411-22. PubMed ID: 16735938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W; El-Samalouti V; Gerlinger C; Schaefers M
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
    White WB; Pitt B; Preston RA; Hanes V
    Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women.
    Dunkin J; Rasgon N; Wagner-Steh K; David S; Altshuler L; Rapkin A
    Psychoneuroendocrinology; 2005 Apr; 30(3):284-96. PubMed ID: 15511602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms.
    Sutter G; Schmelter T; Gude K; Schaefers M; Gerlinger C; Archer DF
    Menopause; 2014 Mar; 21(3):236-42. PubMed ID: 23963309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial.
    Steiner AZ; Hodis HN; Lobo RA; Shoupe D; Xiang M; Mack WJ
    Menopause; 2005; 12(6):728-33. PubMed ID: 16278616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hot flashes and estrogen therapy do not influence cognition in early menopausal women.
    LeBlanc ES; Neiss MB; Carello PE; Samuels MH; Janowsky JS
    Menopause; 2007; 14(2):191-202. PubMed ID: 17194963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
    Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
    Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial.
    Shah S; Bell RJ; Savage G; Goldstat R; Papalia MA; Kulkarni J; Donath S; Davis SR
    Menopause; 2006; 13(4):600-8. PubMed ID: 16837882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of 17beta-estradiol over 3 months without progestin co-administration does not improve coronary flow reserve in post-menopausal women: a randomized placebo-controlled cross-over CMR study.
    Schwitter J; Kozerke S; Bremerich J; Baltes C; Attenhofer Jost C; Birkhäuser M; Boesiger P; Buser P
    J Cardiovasc Magn Reson; 2007; 9(4):665-72. PubMed ID: 17578722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
    Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
    J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.